Role of red blood cells in pharmacokinetics of chemotherapeutic agents

Anti-Cancer Drugs

Volumn 10, Issue 2, 1999, Pages 147-153

  Schrijvers, Dirk ^a,d   Highley, Martin ^b   De Bruyn, Ernst ^c   Van Oosterom, Allan T ^c   Vermorken, Jan B ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d Department of Medical Oncology ^*  (Belgium)

Author keywords

Chemotherapy; Metabolization; Red blood cell; Storage; Transport

Indexed keywords

7 N [2 [[2 (GAMMA GLUTAMYLAMINO)ETHYL]DITHIO]ETHYL]MITOMYCIN C; ALPHA2B INTERFERON; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ASPARAGINASE; CAMPTOTHECIN; CISPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; IFOSFAMIDE; MERCAPTOPURINE; MESNA; METHOTREXATE; MITOMYCIN C; OXALIPLATIN; PACLITAXEL; PLASMA PROTEIN; RANITIDINE; TIOGUANINE; VINBLASTINE;

ACUTE LYMPHOCYTIC LEUKEMIA; BLOOD TOXICITY; BRAIN DISEASE; CLINICAL TRIAL; COMA; CONFUSION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG STORAGE; DRUG TRANSPORT; ERYTHROCYTE; GASTROINTESTINAL SYMPTOM; HEMORRHAGIC CYSTITIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; LUNG TOXICITY; NONHODGKIN LYMPHOMA; ORAL DRUG ADMINISTRATION; PLASMA; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; SOMNOLENCE; THROMBOCYTOPENIA;

EID: 0033066996     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199902000-00002     Document Type: Review

References (33)

1. Hsia CCW. Mechanisms of disease: respiratory function of hemoglobin. N Eng J Med 1998; 4: 239-47.
2. Highley MS, De Bruijn EA. Erythrocytes and the transport of drugs and endogenous compounds. Pharm Res 1996; 13: 186-95.
3. Keuzenkamp-Jansen CW, De Abreu RA, Bokkerink JPM, Trijbels JMF. Determination of extracellular and intracellular thiopurines and methylthiopurines by high-performance liquid Chromatography. J Chromatogr B Biomed Appl 1995; 672: 53-61.
4. Rabel SR, Stobaugh JF, Trueworthy R. Determination of intracellular levels of 6-mercaptopurine metabolites in erythrocytes utilizing capillary electrophoresis with laser-induced fluorescence detection. Anal Biochem 1995; 224: 315-22.
5. Rostami-Hodjegan A, Lennard L, Lilleyman JS. The accumulation of mercaptopurine metabolites in age fractionated red blood cells. Br J Clin Pharmacol 1995; 40: 217-22.
6. Bostrom B, Erdmann G. Cellular pharmacology of 6-mercaptopurine in acute lymphoblastic leukemia. Am J Pediatr Hematol Oncol 1993; 15: 80-6.
7. Lena N, Imbert AM, Brunet P, Cano JP, Carcassonne Y. Kinetics of methotrexate and its metabolites in red blood cells. Cancer Drug Deliv 1987; 4: 119-27.
8. Flynn G, McHale L, McHale AP. Methotrexate-loaded, photosensitized erythrocytes: a photoactivatable carrier/delivery system for use in cancer therapy. Cancer Lett 1994; 82: 225-9.
9. Schroder H, Clausen N, Ostergard t, Pressler T. Folic acid supplements in vitamin tablets: a determinant of hematological drug tolerance in maintenance therapy of childhood acute lymphoblastic leukemia. Pediatr Hematol Oncol 1986; 3: 241-7.
10. Graham ML, Shuster JJ, Kamen BA, et al. Red blood cell methotrexate and folate levels in children with acute lymphoblastic leukemia undergoing therapy: a Pediatric Oncology Group pilot study. Cancer Chemother Pharmacol 1992; 31: 217-22.
11. Wattanatorn W, McLeod HL, Cassidy J, Kendle KE. High-performance liquid Chromatographic assay of 5-fluorouracil in human erythrocytes, plasma and whole blood. J Chromatogr B Biomed Appl 1997; 692: 233-7.
12. Czejka M, Schüller J, Fogl U. Pharmakokinetik von 5-Fluorouracil nach i.v.-gabe unter berücksichtigung der erythrozyten. Arch Pharm 1992; 325: 73-5.
13. Baerlocher GM, Beer JH, Owen GR, Meiselman HJ, Reinhart WH. The antineoplastic drug 5-fluorouracil produces echinocytosis and affects blood rheology. Br J Haematol 1997; 99: 426-3.
14. Kravtzoff R, Colombat P, Desbois I, et al. Tolerance evaluation of L-asparaginase loaded in red blood cells. Eur J Clin Pharmacol 1996; 51: 221-5.
15. Colombo T, Broggini M, Garattini S, Grazia Donelli M. Differential adriamycin distribution to blood components. Eur J Drug Metab Pharmacokinet 1981; 6: 115-22.
16. De Flora A, Benatti U, Guida L, Zocchi E. Encapsulation of adriamycin in human erythrocytes. Proc Natl Sci Acad USA 1986; 83: 7029-33.
17. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy, N Eng J Med 1998; 339: 900-5.
18. Czejka MJ, Schüller J, Weiss C, Meyer B. Disposition of epirubicin and its aglycone in serum and red blood cells after high-dose i.v. bolus. Int J Exp Clin Chemother 1992; 5: 193-8.
19. Pernkopf I, Tesch G, Dempe K, Kletzl H, Schüller J, Czejka M. In vitro-untersuchungen zur binding von epirubicin an humane plasmaproteine und erythrozyten: interaktion mit dem zytoprotektivum amifostin. Pharmazie 1996; 51: 897-901.
20. Bandak S, Czejka M, Schüller J, Schemhammer E. Pharmacokinetic drug interaction between epirubicin and interferon-α-2b in serum and red blood cells. Arzneim Forsch Drug Res 1995; 45: 212-5.
21. Vermorken JB, van der Vijgh WJF, Klein I, Hart AAM, Gall HE, Pinedo HM. Pharmacokinetics of free and total platinum species after short-term infusion of cisplatin. Cancer Treat Rep 1984; 68: 505-13.
22. Van Der Vijgh WJF. Clinical pharmacokinetics of carboplatin. Clin Pharmacokinet 1991; 21: 242-61.
23. Long DF, Patton TF, Repta AJ. Platinum levels in human erythrocytes following intravenous administration of cisplatin: importance of erythrocytes as a distribution site for platinum species. Biopharm Drugs Disp 1981; 2: 137-46.
24. Elferink F, Van der Vijgh WJF, Klein I, et al. Pharmacokinetics of carboplatin after i.v. administration. Cancer Treatment Reports 1987; 71: 1231-7.
25. Grumblat A, Peytavin G, Vayre P, Chapius P, Fredj G, Mathe G. Pharmacokinetics of oxaliplatin compared after intraperitoneal and intravenous administration. Bull Cancer 1989, 76: 887-8.
26. Pendyala L, Creaven PJ. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res 1993; 53: 5970-6.
27. Dechant KL, Brogden RN, Pilkington T, Faulds D. Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer. Drugs 1991; 42: 428-67.
28. Momerency G, Van Cauwenberghe K, Highley MS, Harper PG, Van Oosterom AT, De Bruijn EA. Partitioning of ifosfamide and its metabolites between red blood cells and plasma. J Pharm Sci 1996; 85: 262-5.
29. Highley MS, Schrijvers D, Van Oosterom AT, et al. Activated oxazaphosphorines are transported predominantly by erythrocytes. Ann Oncol 1997; 8: 1139-44.
30. Kumar GN, Walle UK, Bhalla KN, Walle T. Binding of taxol to human plasma, albumin and alpha 1-acid glycoprotein. Res Commun Chem Pathol Pharmacol 1993; 80: 337-44.
31. Mi Z, Burke TG. Differential interactions of camptothecin lactone and carboxylate forms with human blood components. Biochemistry 1994; 33: 10325-36.
32. Highley MS, Schrijvers D, Slee P, et al. Location of activated oxazophosphorines in erythrocytes. Proc Am Ass Cancer Res 1996; 37: 178-1222.
33. Jacob H, Amsden T, White J. Membrane microfilaments of erythrocytes: alteration in intact cells reproduces the hereditary spherocytosis syndrome. Proc Natl Acad Sci USA 1972; 69: 471-4.